[12] Patent
[11] Patent No.:GC0007617  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126221
Date of the Decision to Grant the Patent:19/Apr/2018

[21] Application No.:GC 2013-24530

[22] Filing Date:29/5/2013

[30] Priority:

[33] State [32] Priority date [31] Priority No.
EP
31/5/2012
12004186.8

[72] Inventors:1- Christian GEGE،2- Christoph STEENECK،3- Dr. Olaf KINZEL،4- Dr. Gerald KLEYMANN،5- Thomas HOFFMANN

[73] Owner: Phenex Pharmaceuticals AG, Donnersbergweg 1, 67059, Ludwigshafen, Germany

[74] Agent: Abu-Gazaleh Intellectual Property L.L.C

  

 

  

[51]IPC:
Int. Cl.: C07D 277/36, 277/56, 417/04, 417/06, 417/12, 455/02, 495/10 (2006.01)

[56] Cited Documents:

-WO 2012/027965 A1 (GLAXO GROUP LTD [GB]; WANG YONGHUI [CN]; CAI WEI [CN]; LIU QIAN [CN];) 08 March 2012
-WO 2012/028100 A1 (GLAXO GROUP LTD [GB]; WANG YONGHUI [CN]; YANG TING [CN]; LIU QIAN [CN]) 08 March 2012
-WO 2007/125049 A1 (SOLVAY PHARM GMBH [DE]; ANTEL JOCHEN [DE]; GREGORY PETER-COLIN [DE]; L) 08 November 2007
-WO 2008/083070 A1 (NEUROGEN CORP [US]; BAKTHAVATCHALAM RAJAGOPAL [US]; ZHANG LUYAN [US];) 10 July 2008
-WO 2007/087427 A2 (VO NHA H [US] ET AL VO NHA HUU [US] ET AL) 02 August 2007
-WO 2006/004984 A1 (VERTEX PHARMA [US]; PIERARD FRANCOISE [GB]; JIMENEZ JUAN-MIGUEL [GB];) 12 January 2006
-WO 2012/064744 A2 (LYCERA CORP [US]; GLICK GARY D [US]; TOOGOOD PETER L [US]; ROMERO ARTH) 18 May 2012
 
Examiner: PH. Neda J. AlMuallem

[54] CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR RORy
[57] Abstract: The invention provides modulators for the orphan nuclear receptor ROR? and methods for treating ROR? mediated diseases by administering these novel ROR? modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compounds of Formula (1), (1'), (100), (100'), (200) and (200') , , , , and and the enantiomers, diastereomers, tautomers, N-oxides, solvates and pharmaceutically acceptable salts thereof.
No. of claims: 29


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.